An open label, multicenter, randomized crossover study of two routine prophylaxis regimens of moroctocog alfa (AF-CC) compared to on-demand (OD) therapy in 2 cohorts of children with hemophilia A
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Moroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- 22 Jan 2019 New trial record
- 04 Dec 2018 Primary endpoint (Prophylaxis reduces ABR relative to OD therapy) has been met, as reported in an abstract presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology